source
- China rises on biotech risk list as US draft rules threaten Chinese biopharma investmentsA recent Signal Survey shows China moving up the biotech industry’s concern list even before the Treasury Department issued draft rules that could curb U.S. investment in Chinese biopharma. The pr…
- Analysts predict biopharma gains as Democrats take Congress controlAnalysts say the biopharma sector is set to benefit from the recent shift in U.S. Congress, with Democrats now holding majorities in both the House and Senate. They note that drug‑pricing debates…